<DOC>
	<DOCNO>NCT00979134</DOCNO>
	<brief_summary>This study primarily design assess safety tolerability AZD4547 increase dos patient advance solid malignancy standard medication option available . It also assess blood level action AZD4547 body period time .</brief_summary>
	<brief_title>Study Designed Assess Safety Tolerability AZD4547 Increasing Doses Patients With Advanced Tumours</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Minimum life expectancy 12 week The presence solid , malignant tumour resistance standard therapy standard therapy exist In expansion study patient must tumour least 1cm size measure use CT MRI scan , provide tumour sample sponsor company test FGFR1 and/or 2 amplification Expansion , 5 group advance cancer Solid tumour , FGFR1 and/or FGFR2 gene amplify Squamous NSCLC , FGFR1 gene low &amp; high amplify Gastric adenocarcinoma , include low oesophagus/gastrooesophageal junction , FGFR2 gene low &amp; high amplify Aged least 25 year Treatment chemotherapy , immunotherapy anticancer agent within 3 week first dose study An inability able take study medication A bad reaction AZD4547 drug similar structure class .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Tumour</keyword>
	<keyword>Advanced Solid Malignancies</keyword>
	<keyword>FGFR</keyword>
	<keyword>Squamous NSCLC</keyword>
	<keyword>Gastric adenocarcinoma</keyword>
</DOC>